Jubilant Ingrevia Ltd Q3 FY2023 Concall Summary

Key Takeaways

• A quarter of two halves: Specialty Chemicals grew absolute EBITDA 15% on higher volumes, while Nutrition & Health Solutions revenue fell 39% as avian and swine flu crushed Niacinamide demand, dragging consolidated EBITDA down 29% YoY.
• The Nutrition hit is framed as temporary: Management calls the flu-driven demand destruction a once-in-two-decades event that "is not going to long last," and is already seeing China demand improve post-COVID reopening.
• Capex plan revised upward to ₹2,275 Cr: Incremental spend targets nutraceuticals, R&D/CDMO expansion, and debottlenecking, reinforcing the FY'27 revenue mix target of 65% Specialty + Nutrition.
• Energy cost is the silent margin drag: Non-availability of contracted coal and high imported coal prices compressed margins; a multi-pronged efficiency program is underway but management won't quantify the benefit for "a couple of quarters."
• What to watch next quarter: Whether softening coal costs and the Gajraula road-transport coal fix actually flow through to margins, the pace of Niacinamide volume recovery, and commissioning of the cGMP and Acetic Anhydride plants.

Segment Performance

• Specialty Chemicals margin walk: Sequential EBITDA margin improvement came from volume growth and partial pass-through of cost increases. Management expects softening coal prices plus already-taken price increases to deliver better results going forward, but declined to commit to a specific margin floor.
• Nutrition demand signals: China reopening is improving nutraceutical demand; Southeast Asia showing positive traction for Choline Chloride and premixes. The domestic food and cosmetic-grade vitamin B3 business is growing, and new capacity for cosmetic grades is imminent.
• Diketene turning a corner: Demand for Diketene derivatives is improving after a very weak prior quarter; management targets 70–75% utilization in FY'24, with Phase 2 investments earmarked for forward integration into value-added building blocks rather than commodity sales.

Rajesh Srivastava: "This is the first time in last 2 decades, I know this business, this kind of flu has never extended to 2 or 3 quarters. But nevertheless, it is not going to long last."

Nutrition & Health Solutions: The Recovery Bet

• The Niacinamide downdraft: Revenue de-grew 39% as avian and swine flu in Europe and the US, plus severe COVID restrictions in China, created excess inventory across the value chain. EBITDA fell significantly on both lower volumes and lower price realization.
• Why management calls it short term: The flu outbreak's duration (2–3 quarters) is unprecedented in two decades; China's reopening is already improving demand; and the company is using the downturn to shift mix toward more resilient food and cosmetic applications.
• The mix-shift lever: Revenue mix target for Vitamin B4 and B3 is moving from 70:30 (animal feed:food & cosmetic) toward 50:50. New capacity for cosmetic-grade vitamin B3 is being added, and the company plans to enter vitamin B4 for the food segment.
• Domestic strength as a partial offset: Choline Chloride and specialty premixes grew in both volume and value YoY and QoQ in the domestic market, with positive demand traction from Southeast Asia as well.

Rajesh Srivastava: "We have additionally made the investment plan for the nutraceutical segment because that is going to give us much more sustainability and resilience to our profitability and revenue going forward."

Capex & Capacity: Building for the Mix Shift

• Capex plan revised upward: From ₹2,050 Cr to ₹2,275 Cr for FY22–FY25, covering three incremental areas: debottlenecking, ~₹100 Cr increase in the nutraceutical segment (vitamin B4 food business), and R&D expansion driven by good CDMO traction.
• Near-term commissioning milestones: The new GMP and non-GMP CDMO facilities are delayed by a couple of months and expected in the next two months. The Acetic Anhydride plant at Bharuch is nearing completion and expected ready during Q4 FY23.
• Diketene Phase 2: Investments will come "very soon" for forward integration into value-added building blocks. The endeavor is explicitly not to sell the 8,000-ton capacity as a commodity; Phase 2 will add higher-realization products. FY'24 utilization targeted at 70–75%, potentially higher if demand improves.
• cGMP plant ramp-up confidence: Based on orders already received and additional traction that drove further expansion, first-year utilization is expected above 70%. The non-cGMP plant carries a similarly positive outlook.
• Fluorination and food-grade acetic acid: Fluorination capex is still in development/scale-up, with an announcement hoped for next year. Food-grade acetic acid is under regulatory approval; commercial supplies start end of this quarter, with revenue realization in the next financial year after a 5–6 month FSSAI process.

Rajesh Srivastava: "So from where we are seeing, I'm sure you're also seeing the same angle, what we have said for FY'27 is still standing true, and all the investments which we have planned has no change. What is changing is mostly short term..."

Energy Cost: The Margin Overhang

• The coal problem: Contracted coal was not available at the Gajraula site, forcing reliance on higher-cost alternatives. Power and fuel costs rose from 14% to 15% of revenue because softening of coal prices only materialized at end-December/January, so Q3 bore high costs throughout.
• The fix is multi-pronged: From Q4, the company can take contractual coal at contractual price via road transportation to Gajraula (not 100% benefit, but meaningful). A broader energy efficiency program spans grid power sourcing at Gajraula, renewable sources, and digital interventions to improve generation efficiency.
• No quantification yet: Management declined to put a number on the margin benefit, stating partners are still working to harden the figures. A "significant improvement in overall profitability" is promised once all initiatives are implemented, but investors must wait "a couple of quarters" for specifics.
• The pass-on risk: Management explicitly warned that any reduction in imported coal prices will invite customer demands for price pass-backs, just as cost increases were partially passed on. The net margin benefit is not a simple mathematical calculation.

Rajesh Srivastava: "But remember that any reduction in coal price imported, customers are also smart, they will ask for a pass on. As we take increase in pass on, they will also ask reduction in pass-on. So please don't just calculate in mathematics and highlight out."

CDMO & Specialty Chemicals: The Structural Growth Engine

• CDMO pipeline is healthy and progressing: New GMP and non-GMP facilities, though slightly delayed, are expected commissioned in the next two months. R&D expansion is being funded because CDMO traction is strong, and the cGMP plant already has orders supporting >70% first-year utilization.
• Pyridine and derivatives driving volume: Significant volume improvement came from increased pyridine and pyridine derivatives offtake, with higher demand from Chinese customers. Current utilization is 70–75%; debottlenecking capex will add headroom.
• Acetic Anhydride structural tightness: Global demand continues to grow across use segments with no new capacity coming up globally. The new Bharuch plant, ready in Q4 FY23, lets the company leverage a supply-constrained market.
• Diketene as the next leg: Phase 1 utilization is ramping toward 70–75% in FY'24; Phase 2 will forward-integrate into value-added building blocks. Management is confident enough to call the investment "very soon."

Rajesh Srivastava: "Global demand of Acetic Anhydride continues to grow in several use segments and there is no new capacity coming up globally, while we continue to leverage our capacity from existing as well newly built plant."

Guidance & Commitments

Key Metrics